KAVIGALE

This brand name is authorized in Austria, Lithuania.

Active ingredients

The drug KAVIGALE contains one active pharmaceutical ingredient (API):

1	Sipavibart UNII 977D2P9YYW - SIPAVIBART
	Sipavibart is a recombinant human IgG1 monoclonal antibody that provides passive immunisation by binding the SARS-CoV-2 spike protein receptor binding domain (RBD). Sipavibart is long-acting, with amino acid substitutions to extend antibody half-life (YTE) and to reduce antibody effector function and potential risk of antibody-dependent enhancement of disease (TM).
	Read more about Sipavibart

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KAVIGALE Solution for injection/infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BD09		J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BD Antiviral monoclonal antibodies
Discover more medicines within J06BD09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
LT	Valstybinė vaistų kontrolės tarnyba	1102460